Study Design
DesignRandomized, double-blind, active-controlled
BlindingDouble-blind
Enrollment1224
Duration60 weeks
Treatment Arms
Ixekizumab 80mg Q2W 160mg Wk 0, then 80mg q2w (Wk 2-12), then 80mg q4w n=351
Ixekizumab 80mg Q4W 160mg Wk 0, then 80mg q4w n=347
Etanercept 50mg BIW 50mg SC twice weekly n=358
Placebo Matching placebo n=168
[{"id":"pasi75-w12","name":"PASI 75 at Week 12","type":"PRIMARY","unit":"%","results":[{"value":89.7,"arm_id":"ix80-arm","p_value":0.001},{"value":77.5,"arm_id":"ix80q4-arm"},{"value":41.6,"arm_id":"etn-arm"},{"value":2.4,"arm_id":"pbo-arm"}],"timepoint":"Week 12"}]